1Zaoutis TE, Argon J, Chu J, et al. The epidemiolog and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis [ J ]. Clin Infect Dis, 2005, 41 (9): 1232 - 1239.
2Segal BH, Herbrecht R, Steuens DA, et al.Defining responses to therapy and study outcomes in clinical trial of invasive fungal diseases: Mycoses study Group and European Organization for Research and Treatment of Cancer consensus criteria [ J ]. Clin Infect Dis, 2008, 47 (5): 674-683.
3Boogaerts M, Winston DJ, Bow EJ, et al.Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad - spectrum antibacterial therapy. A randomized, controlled trial [J]. Ann Intern Med, 201, 135 (6): 412 -422.
4Walsh T J, Pappas P, Winston D J, et al. Voriconazole compared with liposomal amphoteriein B for empirical antifungal therapy in patients with neutropenia and persistent fever [J] .N Engl J Med, 2002, 346 (4): 225 - 234.
7Chowdhry R, Marshall WL.Antifungal therapies in the intensive care unit [ J] . Intensive Care Med, 2008, 23 (3): 151-158.
8Parkins MD, Sabuda DM, Elsayed S, et aL Adequacy of empirical antifungal therapy and effect of outcome among patients with invasive Candida species infections [J]. Antimicrob Chemother, 2007, 60 (3): 613- 618.
9Chen H, Suda KJ, Turpin RS, et al. High - versus low - dose fluconazole therapy for empiric treatment of suspected invasive candidiusis among high - risk patients in the intensive care unit: a cost - effectiveness analysis [ J ]. Curr med Res Opin, 2007, 23 (5): 1057- 1065.
10Garnacho - Montero J, Amaya - ViUar R, Ortiz - Leyb C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome [ J ] . Crit Care, 2005, 9 (3) : R191 -199.
9Mora-Duarte J,Belts R,Rotstein C,et al.Comparison of caspofungin and amphotericin B for invasive candidiasis[J].N Engl J Med,2002,347:2020-2029.
10Maertens J,Raad I,Petrikkos G,et al.Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy[J].Clin Infect Dis,2004,39:1 563-1 571.
